Literature DB >> 26770593

Identification of plasma vascular endothelia-cadherin as a biomarker for coronary artery disease in Type 2 diabetes mellitus patients.

Yan Yan1, Qingqing Chang1, Quanmin Li1, Lin Li1, Shuang Wang1, Ruiqin Du1, Xiaoqiang Hu1.   

Abstract

OBJECTS: To examine how vascular endothelia (VE)-cadherin plasma levels are correlated with parameters associated with endothelial function such as endothelin-1, nitric oxide, nitric oxide synthase and HbA1c in type 2 diabetic patients with coronary artery disease.
METHODS: VE-cadherin levels were analyzed by enzyme-linked immunosorbent assays. Spearman's correlation and multiple stepwise regression analyses were used to examine the relationship between plasma VE-cadherin and other factors.
RESULTS: By univariate correlation analysis, plasma VE-cadherin levels were significantly associated with age, total cholesterol, triglyceride, hemoglobin A1c, and endothelin-1. Multiple regression analysis (adjusted for age, total cholesterol, and triglyceride) showed that plasma VE-cadherin levels were independently and significantly associated with HbA1c and ET-1. Plasma VE-cadherin levels were significantly highest in patients with diabetes mellitus and coronary artery disease. While patients with diabetes mellitus had higher levels of VE-cadherin compared with healthy subjects.
CONCLUSIONS: This study found that VE-cadherin levels might be a biomarker for some endothelial dysfunction associated with coronary artery disease in type 2 diabetes mellitus.

Entities:  

Keywords:  Vascular endothelia-cadherin; coronary artery disease; type 2 diabetes mellitus

Year:  2015        PMID: 26770593      PMCID: PMC4694493     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice.

Authors:  Peter J Kuhlencordt; Stefanie Hötten; Johannes Schödel; Sebastian Rützel; Kai Hu; Julian Widder; Alexander Marx; Paul L Huang; Georg Ertl
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-20       Impact factor: 8.311

Review 2.  Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management.

Authors:  K Tziomalos; V G Athyros; A Karagiannis; D P Mikhailidis
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-10-14       Impact factor: 4.222

3.  Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells.

Authors:  T J Wright; L Leach; P E Shaw; P Jones
Journal:  Exp Cell Res       Date:  2002-11-01       Impact factor: 3.905

4.  Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products.

Authors:  U Chakravarthy; R G Hayes; A W Stitt; E McAuley; D B Archer
Journal:  Diabetes       Date:  1998-06       Impact factor: 9.461

Review 5.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

Review 6.  VE-cadherin: at the front, center, and sides of endothelial cell organization and function.

Authors:  Elizabeth S Harris; W James Nelson
Journal:  Curr Opin Cell Biol       Date:  2010-08-11       Impact factor: 8.382

7.  Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Hidenobu Koga; Seigo Sugiyama; Kiyotaka Kugiyama; Keisuke Watanabe; Hironobu Fukushima; Tomoko Tanaka; Tomohiro Sakamoto; Michihiro Yoshimura; Hideaki Jinnouchi; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

8.  Relaxin is a candidate drug for lung preservation: relaxin-induced protection of rat lungs from ischemia-reperfusion injury.

Authors:  Konstantin Alexiou; Klaus Matschke; Angelika Westphal; Karl Stangl; Thomas Dschietzig
Journal:  J Heart Lung Transplant       Date:  2009-12-24       Impact factor: 10.247

9.  Diabetic retinopathy and vascular endothelial growth factor.

Authors:  Majid Khazaei
Journal:  J Res Med Sci       Date:  2013-06       Impact factor: 1.852

10.  Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.

Authors:  Andrzej Surdacki; Olga Kruszelnicka; Tomasz Rakowski; Aleksandra Jaźwińska-Kozuba; Jacek S Dubiel
Journal:  Cardiovasc Diabetol       Date:  2013       Impact factor: 9.951

View more
  5 in total

1.  Low Ethanol Concentrations Promote Endothelial Progenitor Cell Capacity and Reparative Function.

Authors:  Lars Brodowski; Bianca Schröder-Heurich; Berina Kipke; Cara Schmidt; Constantin S von Kaisenberg; Frauke von Versen-Höynck
Journal:  Cardiovasc Ther       Date:  2020-09-22       Impact factor: 3.023

2.  Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.

Authors:  Ka Ka Ting; Yang Zhao; Weiyong Shen; Paul Coleman; Michelle Yam; Tailoi Chan-Ling; Jia Li; Thorleif Moller; Mark Gillies; Mathew A Vadas; Jennifer R Gamble
Journal:  Diabetologia       Date:  2018-11-15       Impact factor: 10.122

3.  The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.

Authors:  Rui Shi; Lei Zhao; Yun Qi
Journal:  BMC Ophthalmol       Date:  2018-04-18       Impact factor: 2.209

4.  Human iPSCs-Derived Endothelial Cells with Mutation in HNF1A as a Model of Maturity-Onset Diabetes of the Young.

Authors:  Neli Kachamakova-Trojanowska; Jacek Stepniewski; Jozef Dulak
Journal:  Cells       Date:  2019-11-14       Impact factor: 6.600

5.  Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions.

Authors:  Rayana A P Maciel; Regiane S Cunha; Valentina Busato; Célia R C Franco; Paulo C Gregório; Carla J R Dolenga; Lia S Nakao; Ziad A Massy; Agnès Boullier; Roberto Pecoits-Filho; Andréa E M Stinghen
Journal:  Toxins (Basel)       Date:  2018-10-07       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.